Food and Drug Administration (FDA) Disclosure:

The statements in this forum have not been evaluated by the Food and Drug Administration and are generated by non-professional writers. Any products described are not intended to diagnose, treat, cure, or prevent any disease.

Website Disclosure:

This forum contains general information about diet, health and nutrition. The information is not advice and is not a substitute for advice from a healthcare professional.

British Journal of Pharmacology-The Cannabinoid Issue

Discussion in 'Medical Marijuana Usage and Applications' started by tharedhead, Nov 18, 2011.

  1. #1 tharedhead, Nov 18, 2011
  2. #2 ocsurfer, Nov 18, 2011
    Great find!

    I haven't read all of the articles at the site, but this one caught my eye right away:

    Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

    THC has already been legalized in the US in the form of Marinol (currently only synthetic THC is used, however the DEA may reschedule organic THC for use in generic versions of Marinol).

    Organic THC and CBD may be next for FDA approval in the form of Sativex.

    We need more studies involving whole plant cannabis, including all potentially therapeutic phytocannabinoids and other terpenoids contained in cannabis. That is how we will get cannabis rescheduled instead of just the "components" of cannabis.

    The popular opinion amongst medical cannabis patients seems to be that the "legal" forms of cannabis medicine (Marinol, Sativex, etc...) are just not as effective as, or have more side effects than whole plant cannabis.

    :)
     

Share This Page